Search

Your search keyword '"B Ataseven"' showing total 42 results

Search Constraints

Start Over You searched for: Author "B Ataseven" Remove constraint Author: "B Ataseven" Database OpenAIRE Remove constraint Database: OpenAIRE
42 results on '"B Ataseven"'

Search Results

17. The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer

18. 382 Molecular classification of endometrial carcinoma substantially changing risk-assessment: Results from a european multicentre initiative

19. 930 Comparison of clinicopathological characteristics and survival outcomes of patients with grade III endometrioid adenocarcinoma and carcinosarcoma

20. 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

22. Management of the axilla for high-risk early breast cancer (EBC) before and after neoadjuvant chemotherapy (NACT): an analysis of the multicentre GeparOcto trial

24. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

25. Vaginale Hysterektomie und beidseitige Adnexektomie in interdisziplinärem Konzept bei Frau zu Mann – Transsexualismus

29. P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer

32. Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability

33. [Vaginal hysterectomy and bilateral adnexectomy for female to male transsexuals in an interdisciplinary concept]

36. Primary cerebral metastasis in bilateral breast cancer

37. 63P Phase III SafeHer study subgroup analyses: Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients

38. 1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

39. [Breast cancer]

40. Safeher: A Study of Assisted- and Self-Administered Subcutaneous Trastuzumab (H-SC) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (EBC)

42. O-44 Evaluation of estrogen and progesterone receptor, Her-2 and Topo IIα in primary breast cancer and metastatic axillary lymph nodes

Catalog

Books, media, physical & digital resources